As of 2026-09-22, the EV/EBITDA ratio of Lineage Cell Therapeutics Inc (LCTX) is -4.15. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LCTX's latest enterprise value is 214.49 mil USD. LCTX's TTM EBITDA according to its financial statements is -51.62 mil USD. Dividing these 2 quantities gives us the above LCTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 2.5x - 3.7x | 3.1x |
| Forward P/E multiples | 2.5x - 3.7x | 3.1x |
| Fair Price | (0.36) - (0.62) | (0.49) |
| Upside | -136.0% - -161.5% | -148.7% |
| Date | EV/EBITDA |
| 2026-09-21 | -4.15 |
| 2026-09-18 | -4.25 |
| 2026-09-17 | -4.25 |
| 2026-09-16 | -4.44 |
| 2026-09-15 | -4.40 |
| 2026-09-14 | -4.44 |
| 2026-09-11 | -4.15 |
| 2026-09-10 | -4.20 |
| 2026-09-09 | -4.25 |
| 2026-09-08 | -4.54 |
| 2026-09-04 | -4.49 |
| 2026-09-03 | -4.59 |
| 2026-09-02 | -4.64 |
| 2026-09-01 | -4.49 |
| 2026-08-31 | -4.59 |
| 2026-08-28 | -4.64 |
| 2026-08-27 | -4.88 |
| 2026-08-26 | -4.69 |
| 2026-08-25 | -4.73 |
| 2026-08-24 | -4.54 |
| 2026-08-21 | -4.49 |
| 2026-08-20 | -4.49 |
| 2026-08-19 | -4.59 |
| 2026-08-18 | -4.40 |
| 2026-08-17 | -4.40 |
| 2026-08-14 | -4.44 |
| 2026-08-13 | -4.40 |
| 2026-08-12 | -4.59 |
| 2026-08-11 | -4.69 |
| 2026-08-10 | -4.73 |
| 2026-08-07 | -4.59 |
| 2026-08-06 | -4.73 |
| 2026-08-05 | -4.78 |
| 2026-08-04 | -4.69 |
| 2026-08-03 | -4.64 |
| 2026-07-31 | -4.49 |
| 2026-07-30 | -4.64 |
| 2026-07-29 | -4.40 |
| 2026-07-28 | -4.44 |
| 2026-07-27 | -4.25 |
| 2026-07-24 | -4.25 |
| 2026-07-23 | -4.44 |
| 2026-07-22 | -4.64 |
| 2026-07-21 | -4.78 |
| 2026-07-20 | -4.59 |
| 2026-07-17 | -4.88 |
| 2026-07-16 | -4.93 |
| 2026-07-15 | -5.17 |
| 2026-07-14 | -5.17 |
| 2026-07-13 | -5.12 |